Targeting tumor microenvironment by a translational multivalent nanomedicine: towards an effective anticancer combination immunotherapy

**Acronym:** Nanotumim  
**Coordinator:** Véronique Préat, Université Catholique de Louvain, Louvain Drug Research Institute, Brussels, Belgium; veronique.preat@uclouvain.be  
**Partners:** Rogério Gaspar, Diego Arango, Sofia Corte-Real

The survival of patients with metastatic colorectal cancer is low; therefore an effective strategy against the heterogeneous population of cancer cells requires a combinatory approach. The Nanotumim project will develop an integrative and multivalent nanotechnology-based therapeutic strategy to manipulate the multiple pro-tumorigenic mechanisms within tumor microenvironment. The project will develop a chemically-defined nanoplatform able to conjugate engineered targeting moieties to in vivo target and modulate distinct cell populations including myofibroblasts, cancer cells, and dendritic cells aiming at reverting the tumor-immune network to a pro-inflammatory environment. This highly innovative nanoplatform will allow the combination of a cytotoxic drug at cancer site with a balanced and multi-targeted immunotherapy that hopefully will improve the outcome of patients with metastatic disease.

“This highly innovative nanoplatform will allow the combination of a cytotoxic drug at cancer site with a balanced and multi-targeted immunotherapy”